Table 2.
Main adverse events recorded in the dose-finding study with ACT-132577 (aprocitentan) in participants with essential hypertension
| Event | Placebo, affected/at risk (%) | Aprocitenten 5 mg, affected/at risk (%) | Aprocitenten 10 mg, affected/at risk (%) | Aprocitenten 25 mg, affected/at risk (%) | Aprocitenten 50 mg, affected/at risk (%) | Lisinopril 20 mg, affected/at risk (%) |
|---|---|---|---|---|---|---|
| Cardiac disorders | ||||||
| LBBB | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 1/82 (1.22%) | 0/81 (0.00%) | 0/81 (0.00%) |
| Atrioventricular block first degree | 0/82 (0.00%) | 1/82 (1.22%) | 0/82 (0.00%) | 1/82 (1.22%) | 0/81 (0.00%) | 0/81 (0.00%) |
| Tachycardia | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 1/82 (1.22%) | 0/81 (0.00%) | 1/81 (1.23%) |
| Fall | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 0/81 (0.00%) | 1/81 (1.23%) |
| Jaw fracture | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 0/81 (0.00%) | 1/81 (1.23%) |
| Neoplasm malignant | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 1/82 (1.22%) | 0/81 (0.00%) | 0/81 (0.00%) |
| Anemia | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 2/82 (2.44%) | 1/81 (1.23%) | 0/81 (0.00%) |
| Hyperthyroidism | 0/82 (0.00%) | 0/82 (0.00%) | 1/82 (1.22%) | 0/82 (0.00%) | 0/81 (0.00%) | 0/81 (0.00%) |
| Dyspepsia | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 1/82 (1.22%) | 0/81 (0.00%) | 0/81 (0.00%) |
| Abnormal hepatic function | 0/82 (0.00%) | 1/82 (1.22%) | 0/82 (0.00%) | 0/82 (0.00%) | 0/81 (0.00%) | 0/81 (0.00%) |
| Headache | 1/82 (1.22%) | 1/82 (1.22%) | 2/82 (2.44%) | 2/82 (2.44%) | 2/81 (2.47%) | 4/81 (4.94%) |
| Renal failure | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 0/82 (0.00%) | 0/81 (0.00%) | 1/81 (1.23%) |
Data were extracted from [29]
LBBB left bundle branch block